Etalocib

WARNING: This product is for research use only, not for human or veterinary use.

Description:Etalocib, also known as LY293111 and VML295, is a novel diaryl ether carboxylic acid derivative, is a potent and selective inhibitor of the lipoxygenase pathway either directly through 5'-lipoxygenase or via antagonism of the leukotriene B4 (LTB4) receptor. LY293111 has antineoplastic activity in a variety of preclinical models.

Price and Availability

Etalocib is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 201310Name: EtalocibCAS#: 161172-51-6Chemical Formula: C33H32FNaO6Exact Mass: 285.30316Molecular Weight: 566.59Elemental Analysis:C, 69.95; H, 5.69; F, 3.35; Na, 4.06; O, 16.94

Synonym:VML295; VML-295; VML 295; LY293111; LY-293111; LY 293111; PDSP1001237; PDSP2001221; Etalocib

IUPAC/Chemical Name:sodium 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy-[1,1'-biphenyl]-4-yl)oxy)propoxy)-2-propylphenoxy)benzoate

InChi Key:GKDIMGQSBSDJNC-UHFFFAOYSA-M

InChi Code:InChI=1S/C33H33FO6.Na/c1-3-9-25-29(12-7-13-30(25)40-31-11-6-5-10-26(31)33(36)37)38-18-8-19-39-32-21-28(35)27(20-22(32)4-2)23-14-16-24(34)17-15-23;/h5-7,10-17,20-21,35H,3-4,8-9,18-19H2,1-2H3,(H,36,37);/q;+1/p-1

SMILES Code:O=C([O-])C1=CC=CC=C1OC2=CC=CC(OCCCOC3=C(CC)C=C(C4=CC=C(F)C=C4)C(O)=C3)=C2CCC.[Na+]

Technical Data

Additional Information

Related CAS#152608-41-8 (Etalocib sodium)161172-51-6 (Etalocib free )

References

1: Saif MW, Oettle H, Vervenne WL, Thomas JP, SpitzerG, Visseren-Grul C, Enas N, Richards DA. Randomized double-blind phaseII trial comparing gemcitabine plus LY293111 versus gemcitabine plusplacebo in advanced adenocarcinoma of the pancreas. Cancer J. 2009Jul-Aug;15(4):339-43. PubMed PMID: 19672152.

2: Adrian TE, Hennig R, Friess H, Ding X. The Role of PPARgammaReceptors and Leukotriene B(4) Receptors in Mediating the Effects ofLY293111 in Pancreatic Cancer. PPAR Res. 2008;2008:827096. Epub 2009 Jan27. PubMed PMID: 19190780; PubMed Central PMCID: PMC2631651.

3: Tong WG, Ding XZ, Talamonti MS, Bell RH, Adrian TE. Leukotriene B4receptor antagonist LY293111 induces S-phase cell cycle arrest andapoptosis in human pancreatic cancer cells. Anticancer Drugs. 2007Jun;18(5):535-41. PubMed PMID: 17414622.

4: Baetz T, Eisenhauer E, Siu L, MacLean M, Doppler K, Walsh W, FisherB, Khan AZ, de Alwis DP, Weitzman A, Brail LH, Moore M. A phase I studyof oral LY293111 given daily in combination with irinotecan in patientswith solid tumours. Invest New Drugs. 2007 Jun;25(3):217-25. Epub 2006Dec 5. PubMed PMID: 17146732.

5: Zhang W, McQueen T, Schober W, Rassidakis G, Andreeff M, Konopleva M.Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest andapoptosis in human anaplastic large-cell lymphoma cells via JNKphosphorylation. Leukemia. 2005 Nov;19(11):1977-84. PubMed PMID:16151469.

6: Hennig R, Ventura J, Segersvard R, Ward E, Ding XZ, Rao SM, JovanovicBD, Iwamura T, Talamonti MS, Bell RH Jr, Adrian TE. LY293111 improvesefficacy of gemcitabine therapy on pancreatic cancer in a fluorescentorthotopic model in athymic mice. Neoplasia. 2005 Apr;7(4):417-25.PubMed PMID: 15967119; PubMed Central PMCID: PMC1501143.

7: Schwartz GK, Weitzman A, O"Reilly E, Brail L, de Alwis DP, CleverlyA, Barile-Thiem B, Vinciguerra V, Budman DR. Phase I and pharmacokineticstudy of LY293111, an orally bioavailable LTB4 receptor antagonist, inpatients with advanced solid tumors. J Clin Oncol. 2005 Aug10;23(23):5365-73. Epub 2005 Jun 6. PubMed PMID: 15939925.

8: Ding XZ, Talamonti MS, Bell RH Jr, Adrian TE. A novel anti-pancreaticcancer agent, LY293111. Anticancer Drugs. 2005 Jun;16(5):467-73. Review.PubMed PMID: 15846111.

9: Hennig R, Ding XZ, Tong WG, Witt RC, Jovanovic BD, Adrian TE. Effectof LY293111 in combination with gemcitabine in colonic cancer. CancerLett. 2004 Jul 8;210(1):41-6. PubMed PMID: 15172119.

10: Tong WG, Ding XZ, Hennig R, Witt RC, Standop J, Pour PM, Adrian TE.Leukotriene B4 receptor antagonist LY293111 inhibits proliferation andinduces apoptosis in human pancreatic cancer cells. Clin Cancer Res.2002 Oct;8(10):3232-42. PubMed PMID: 12374694.